Division of Vascular Surgery, Department of Surgery, University of Wisconsin School of Medicine and Public Health, 1111 Highland Ave, WIMR 5137, Madison, WI 53705, USA.
Int J Mol Sci. 2020 Oct 31;21(21):8174. doi: 10.3390/ijms21218174.
Cardiovascular diseases, including peripheral arterial and venous disease, myocardial infarction, and stroke, are the number one cause of death worldwide annually. In the last 20 years, the role of necroptosis, a newly identified form of regulated necrotic cell death, in cardiovascular disease has come to light. Specifically, the damaging role of two kinase proteins pivotal in the necroptosis pathway, Receptor Interacting Protein Kinase 1 (RIPK1) and Receptor Interacting Protein Kinase 3 (RIPK3), in cardiovascular disease has become a subject of great interest and importance. In this review, we provide an overview of the current evidence supporting a pathologic role of RIPK1 and RIPK3 in cardiovascular disease. Moreover, we highlight the evidence behind the efficacy of targeted RIPK1 and RIPK3 inhibitors in the prevention and treatment of cardiovascular disease.
心血管疾病包括外周动脉和静脉疾病、心肌梗死和中风，是全球每年头号死亡原因。在过去的 20 年中，细胞坏死的一种新形式——程序性坏死（regulated necrotic cell death），在心血管疾病中的作用逐渐被揭示。具体来说，在程序性坏死通路中起关键作用的两种激酶蛋白——受体相互作用蛋白激酶 1（RIPK1）和受体相互作用蛋白激酶 3（RIPK3）——在心血管疾病中的损伤作用已成为一个备受关注和重要的课题。在这篇综述中，我们概述了目前支持 RIPK1 和 RIPK3 在心血管疾病中发挥病理性作用的证据。此外，我们还强调了靶向 RIPK1 和 RIPK3 抑制剂在预防和治疗心血管疾病方面的有效性的证据。
Zotero 插件